Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Abecma vs Talvey: how two US-approved medicines for multiple myeloma compare

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Abecma vs Talvey: the short answer

Abecma and Talvey are both US FDA-approved for multiple myeloma, but for different patients and in different ways. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: multiple myeloma.
Main difference: Both are for adults with relapsed or refractory multiple myeloma, but they work differently and are approved at different points.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Abecma and Talvey side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Abecma	Talvey
Generic name	idecabtagene vicleucel^[3]	talquetamab-tgvs^[4]
Type of medicine	BCMA-directed CAR T-cell therapy made from the patient's own T cells^[3]	bispecific antibody (T-cell engager) that targets GPRC5D on myeloma cells and CD3 on T cells^[4]
US-approved for	Adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.^[3]	Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This is an accelerated approval based on response rate and durability of response.^[4]
First US approval (year on the label)	2021^[3]	2023^[4]
How it is given	One-time intravenous infusion. Lymphodepleting chemotherapy (cyclophosphamide and fludarabine for three days) comes first, and Abecma is infused two days after it ends.^[3]	Injection under the skin by a healthcare provider. Treatment starts with step-up doses, then continues at 0.4 mg/kg once weekly or 0.8 mg/kg every 2 weeks.^[4]
Where and what to expect	Patients are told to stay near a healthcare facility for at least one week after the infusion and not to drive for at least one week.^[3]	Patients should be hospitalized for 48 hours after each dose in the step-up schedule.^[4]
Boxed warning	Yes. Cytokine release syndrome, neurologic toxicities, HLH/MAS, prolonged cytopenia, and secondary blood cancers including T-cell malignancies.^[3]	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the TECVAYLI and TALVEY REMS restricted program.^[4]

About multiple myeloma and these two medicines

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell that is part of the immune system. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.^[1]

Abecma is a CAR T-cell therapy. Each dose is made from the patient's own T cells, which are collected, genetically engineered in the manufacturer's laboratory to recognize a protein on cancer cells, grown, and given back by infusion. Talvey is not made from the patient's cells: it is a bispecific antibody that binds CD3 on T cells and GPRC5D on myeloma cells.^{[2, 3, 4]}

The main difference

Both are for adults with relapsed or refractory multiple myeloma, but they work differently and are approved at different points. Abecma is a one-time CAR T-cell infusion after two or more prior lines. Talvey is an injection under the skin given weekly or every 2 weeks after at least four prior lines. Abecma targets BCMA; Talvey targets a different protein, GPRC5D.^{[3, 4]}

The evidence behind each approval

Abecma. Study 1 (NCT03651128) was a randomized, open-label study in 386 adults who had received two to four prior regimens. It compared Abecma with standard regimens chosen by the investigator, and the primary measure was progression-free survival. A second, single-arm study (NCT03361748) enrolled patients after three or more prior lines.^[3]

Talvey. MonumenTAL-1 was a single-arm, open-label study. The label reports response rate and duration of response in 187 patients who had at least four prior lines and no prior T-cell redirection therapy. It also reports results in 32 patients who had received prior T-cell redirection therapy, 81% of whom had received CAR-T therapy.^[4]

No head-to-head trial. Neither US label reports a study that compared Abecma directly with Talvey. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

The Talvey label reports results in 32 patients who had already received T-cell redirection therapy, 81% of them CAR-T therapy and 94% of them treatment directed at BCMA. Neither label sets an order for using the two. Your specialist decides what comes next based on prior treatment.^{[3, 4]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Abecma: common side effects listed on the label include pyrexia (fever), cytokine release syndrome, low antibody levels (hypogammaglobulinemia), infections, musculoskeletal pain and fatigue.^[3]
Talvey: common side effects listed on the label include fever, cytokine release syndrome, taste changes (dysgeusia), nail disorders, musculoskeletal pain, skin disorders, rash, fatigue, weight loss and dry mouth.^[4]

Availability in the Gulf

Abecma: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan
Talvey: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq

How families in the Gulf can access Abecma or Talvey

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[7, 8]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

For Abecma. CAR T-cell therapy is made from the patient's own cells, so treatment happens at a qualified treatment center that can collect the cells, give the lymphodepleting chemotherapy and manage side effects. For most Gulf families that means a referral from the treating specialist. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

A US safety program applies. In the US, Talvey is available only through the TECVAYLI and TALVEY REMS, a restricted program.^[4] The treating hospital must be able to give the step-up doses with hospital monitoring as the label describes.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Abecma or Talvey

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Abecma or Talvey?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Abecma and Talvey?

Are Abecma and Talvey available in Saudi Arabia or the UAE?

Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list.

How can a family in the Gulf get Abecma or Talvey?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy. CAR T-cell therapy is given at a qualified treatment center after a specialist referral.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.